Hematology-Oncology: An Annotated Bibliography of Recent Literature
Authors: HEMATOLOGY-ONCOLOGY COMMITTEE
Journal: Annals of Internal Medicine (1976)

The Literature of Medicine1 June 1976Hematology-Oncology: An Annotated Bibliography of Recent LiteratureReferences to Journal Articles and Other PapersHEMATOLOGY-ONCOLOGY COMMITTEEHEMATOLOGY-ONCOLOGY COMMITTEESearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-84-6-758 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThis bibliography includes references to 78 recently published journal papers and similar sources that represent recent developments important in the concepts and practice of internal medicine. It has been compiled as a part of the work of the Hematology-Oncology Committee toward the preparation of the Medical Knowledge Self-Assessment Program IV Syllabus.In preparing this bibliography, the committee reviewed MEDLINE†bibliographic printouts of journal articles published since the beginning of 1972 and also drew on their own files. Papers were selected with a view to their likely availability in libraries of hospitals and other clinical institutions in the United States and...Disorders of Blood Coagulation Thrombosis Platelet Disorders Anemia Polycythemia Leukemia Neutropenia Chronic Granulomatous Disease Lymphomas Dysproteinemias Solid Tumors1. BENNETTRATNOFF BO: Detection of the carrier state of classic hemophilia. N Engl J Med 288:342-345, 1973 Carriers of classic hemophilia can be detected in most instances by comparing the levels of functional factor VIII and antigenically reactive factor VIII. This study of known and possible carriers shows the value of this approach. CrossrefMedlineGoogle Scholar2. LEVINE P: Efficacy of self-therapy in hemophilia: a study of 72 patients with hemophilia A and B. N Engl J Med 291:1381-1384, 1974 Home therapy and self-therapy of patients with hemophilia have proven very successful from medical, social, and economic points of view, as this paper reports. CrossrefMedlineGoogle Scholar3. WEISS H: Platelet physiology and abnormalities of platelet function. N Engl J Med 293:531-541, 580-588, 1975 An excellent review of platelet physiology and platelet abnormalities, including a detailed exposition of pathophysiology of von Willebrand's disease. CrossrefMedlineGoogle Scholar4. WEISS H: Defects of factor VIII and platelet aggregation —use of ristocetin in diagnosing the von Willebrand syndrome. Blood 45:403-412, 1975 The antibiotic ristocetin has become an important reagent in the study of von Willebrand's disease. This paper discusses its use in the diagnosis of this disease. CrossrefMedlineGoogle Scholar5. BLATTLUNDBLADKINGDON PRH: Thrombogenic materials in prothrombin complex concentrates. Ann Intern Med 81:766-770, 1974 Shows that commercially available prothrombin complex concentrates contain activated procoagulants, probably factors Xa and IXa, which may be thrombogenic. LinkGoogle Scholar6. MERSKEY C: Defibrination syndrome or ... ? Blood 41:599-603, 1973 A provocative discussion of the present uncertainties regarding the concept of disseminated intravascular coagulation. CrossrefMedlineGoogle Scholar7. SHERMANWESSLERAVIOLI LSL: Therapeutic problems of disseminated intravascular coagulation. Arch Intern Med 132:446-453, 1973 An interesting discussion of disseminated intravascular coagulation including pathogenesis, diagnosis, and therapy. The variables to be considered in reaching a decision regarding therapy are reviewed and the means of evaluating therapy discussed. CrossrefMedlineGoogle Scholar8. JACOBSONJACKSON RD: Erythrocyte fragmentation in defibrination syndromes. Ann Intern Med 81:207-209, 1974 Emphasizes that a significant number of patients with disseminated intravascular coagulation have fragmented erythrocytes readily detected on a film of peripheral blood. Marked erythrocyte changes were associated with tissue damage. LinkGoogle Scholar9. MANTHIRSHPINEO MJG: Prolonged prothrombin time and partial thromboplastin time in disseminated intravascular coagulation not due to deficiency of factors V and VIII. Br J Haematol 24:725-734, 1973 Demonstrates that vitamin-K deficiency must be considered in the differential diagnosis of disseminated intravascular coagulation, especially in patients with a prolonged prothrombin time and partial thromboplastin time but a normal thrombin time. CrossrefMedlineGoogle Scholar10. FEINSTEINRAPAPORT DS: Acquired inhibitors of blood coagulation. Prog Hemostatis Thromb 1:75-95, 1972 An excellent review of the subject, including detailed discussion on the "lupus anticoagulant." MedlineGoogle Scholar11. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial. Lancet 2:45-51, 1975 Provides statistically significant data indicating that "minidose" heparin is effective in preventing deep venous thrombosis and pulmonary embolism in postoperative patients. Complications limited to an increase in the number of wound hematomas. MedlineGoogle Scholar12. KAKKAR V: Deep vein thrombosis. Detection and prevention. Circulation 51:8-19, 1975 A detailed review of the detection and prevention of deep vein thrombosis. CrossrefMedlineGoogle Scholar13. O'REILLY R: Interaction of chronic daily warfarin therapy and rifampin. Ann Intern Med 83:506-508, 1975 An example of drug interaction involving warfarin, a problem which is ever present and ever increasing as new drugs are introduced into clinical practice. LinkGoogle Scholar14. GENTONGENTHIRSH EMJ: Platelet inhibiting drugs in the prevention of clinical thrombotic disease. N Engl J Med 293:1174-1178, 1236-1240, 1246-1300, 1975 A complete review of the present status of antiplatelet drugs in the prevention of thrombosis, both arterial and venous. CrossrefMedlineGoogle Scholar15. TEN CATE J: Platelet function tests. Clin Haematol 1:283-294, 1972 A good review of the current tests used to evaluate platelet function. Google Scholar16. MCMILLIANLONGMIREYELENOSKY RRR: Quantitation of platelet-binding IgG produced in vitro by spleens from patients with idiopathic thrombocytopenic purpura. N Engl J Med 291:812-817, 1974 Further laboratory data to explain platelet antibody function in the spleen. CrossrefMedlineGoogle Scholar17. BELLERDOUGLAS FG: Thrombocytopenia indicating Gram-negative infection and endotoxemia. Obstet Gynecol 41:521-524, 1973 It is important for a clinician to recognize the frequency of thrombocytopenia in patients with Gram-negative sepsis. MedlineGoogle Scholar18. RIESPRICE CD: [51Cr] Platelet kinetics in thrombocytopenia. Correlation between splenic sequestration of platelets and response to splenectomy. Ann Intern Med 80:702-707, 1974 Reports that proper positioning of the probe for external surface scanning of the spleen can predict outcome of splenectomy in idiopathic thrombocytopenic purpura. LinkGoogle Scholar19. LOHRMANNBULLDECTER HMJ: Platelet transfusions from HL-A compatible unrelated donors to alloimmunized patients. Ann Intern Med 80:9-14, 1974 HL-A compatible platelet donors can be used effectively for transfusion support of alloimmunized patients. LinkGoogle Scholar20. ABRAMSONEISENBERGASTER NPR: Post-transfusion purpura: immunologic aspects and therapy. N Engl J Med 291:1163-1166, 1974 A detailed study of a case of post-transfusion purpura, with characterization of the antibodies and discussion of treatment by plasmaphoresis. CrossrefMedlineGoogle Scholar21. RHODESDISONSILVER GRD: Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg Gynecol Obstet 136:409-416, 1973 Adds to the evidence that possibly one third of patients receiving heparin may have varying degrees of platelet depression. MedlineGoogle Scholar22. THOMPSONMOOREHESS RRC: Idiopathic thrombocytopenic purpura. Long-term results of treatment and the prognostic significance of response to corticosteroids. Arch Intern Med 130:730-734, 1972 A useful review of the value of steroids versus splenectomy in treatment of idiopathic thrombocytopenic purpura. CrossrefMedlineGoogle Scholar23. VARATADOLPHFOWLER MRN: Cardiovascular effects of anemia. Am Heart J 83:415-426, 1972 A review of hemodynamic changes, compensatory mechanisms to maintain oxygen transport, and clinical cardiovascular findings in anemic patients. CrossrefMedlineGoogle Scholar24. BELLINGHAMGRIMES AA: Red cell 2,3-diphosphoglycerate. Br J Haematol 25:555-562, 1973 A concise summary of our current understanding of the physiologic significance of this compound for oxygen transport. CrossrefMedlineGoogle Scholar25. ROSSE W: Correlation of in vivo and in vitro measurements of hemolysis in hemolytic anemia due to immune reactions. Prog Hematol 8:51-75, 1973 A detailed analysis of the mechanisms by which antibodies and complement mediate erythrocyte destruction in various hemolytic states. MedlineGoogle Scholar26. GARRATTYPETZ GL: Drug-induced immune hemolytic anemia. Am J Med 58:398-407, 1975 Discusses clinical and laboratory characteristics and pathogenetic mechanisms of erythrocyte sensitization in patients with drug-related hemolysis. CrossrefMedlineGoogle Scholar27. SHOHET S: Hemolysis and changes in erythrocyte membrane lipids. N Engl J Med 286:557-583, 638-644, 1972 Provides an overview of composition and metabolism of membrane lipids in normal erythrocytes and reviews the consequences of lipid abnormalities in various disease states. CrossrefMedlineGoogle Scholar28. YAWATAHOWEJACOB YRH: Abnormal red cell metabolism causing hemolysis in uremia. A defect potentiated by tap water hemodialysis. Ann Intern Med 79:362-367, 1973 A study documenting inhibition of the hexose monophosphate shunt by a circulating factor in uremic patients. Chloramine in dialysis bath water can impose critical additional stress on erythrocytes. LinkGoogle Scholar29. CHARACHE S: The treatment of sickle cell anemia. Arch Intern Med 133:698-705, 1974 Part of an excellent symposium on sickle-cell disease, this paper outlines clinical management as practiced by an experienced worker in the field. CrossrefMedlineGoogle Scholar30. PORTNOYHERION BJ: Neurological manifestations in sickle-cell disease. With a review of the literature and emphasis on the prevalence of hemiplegia. Ann Intern Med 76:643-652, 1972 Emphasizes the high prevalence of hemiplegia, convulsions, coma, and visual disturbances in 89 patients with sickle-cell disease, as documented in a retrospective study. LinkGoogle Scholar31. JACOB H: Hypersplenism: mechanisms and management. Br J Haematol 21:1-5, 1974 Summarizes current consensus regarding hypersequestration of formed elements by the spleen and outlines indications for splenectomy. CrossrefGoogle Scholar32. AJLOUNIDOEBLIN KT: The syndrome of hepatitis and aplastic anemia. Br J Haematol 27:345-355, 1974 Case reports and literature review of this increasingly recognized complication of viral hepatitis. Prognosis for marrow recovery is poor. CrossrefMedlineGoogle Scholar33. THOMASSTORBCLIFT ERR: Bone-marrow transplantation. N Engl J Med 292:832-843, 895-902, 1975 A review, from a leading center, of current concepts and practices, obstacles to successful wide-scale application of the technique, and experience to date. CrossrefMedlineGoogle Scholar34. KREMERLASZLO WJ: Hematologic effects of cancer, in Cancer Medicine, edited by HOLLAND JF, FREI E. Philadelphia, Lea and Febiger, 1973, chapter XVII-2, pp. 1085-1099 An analysis of mechanisms causing anemia and abnormalities of platelets, leukocytes, and serum proteins, as commonly seen in cancer patients. Google Scholar35. EICHNER E: The hematologic disorders of alcoholism. Am J Med 54:621-630, 1973 A review of pathogenesis in ethanol-induced anemias (megaloblastic, sideroblastic, and hemolytic), thrombocytopenia, and neutropenia, including comments on neutrophil dysfunction. CrossrefMedlineGoogle Scholar36. STEBBINSSCOTTHERBERT RJV: Drug-induced megaloblastic anemias. Semin Hematol 10:235-251, 1973 Summarizes relationships linking various drugs with abnormal metabolism of folate or B12, or with impaired DNA synthesis. MedlineGoogle Scholar37. DAGGGOLDBERG JA: Detection and treatment of iron deficiency. Clin Haematol 2:365-380, 1973. Discusses clinical and laboratory findings and provides sensible approach to management, with comments on parenteral therapy. Google Scholar38. BERLIN N: Diagnosis and classification of the polycythemias. Semin Hematol 12:339-351, 1975 An excellent discussion of these disorders, part of an interesting seminar on polycythemia. MedlineGoogle Scholar39. HAMMONDWINNICK DS: Paraneoplastic erythrocytosis and ectopic erythropoietin. Ann NY Acad Sci 230:219-227, 1974 An extensive collection of tumors with secondary polycythemia (erythrocytosis). CrossrefMedlineGoogle Scholar40. WARDBLOCK HM: The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome. Medicine (Baltimore) 50:357-420, 1971 A detailed review relating myeloproliferative disease to polycythemia. CrossrefMedlineGoogle Scholar41. LAZLO J: Myeloproliferative disorders (MPD), myelofibrosis, myelosclerosis, extramedullar hematopoiesis, undifferentiated MPD and hemorrhagic thrombocythemia. Semin Hematol 12:409-432, 1975 A good correlative review that includes a section on hemorrhagic thrombocythemia. MedlineGoogle Scholar42. EMERYWHITCOMBFROHLICH AWE: Stress polycythemia and hypertension. JAMA 229:159-162, 1974 A re-emphasis of the elevated hematocrit with hypertension. Some authors have used "spurious" instead of "stress" polycythemia to identify these patients. CrossrefMedlineGoogle Scholar43. JACOB H: The polycythemias and their relationship to erythropoietin. DM 3-26, August 1974 A complete review of current classification, with a discussion of therapy of polycythemia vera. Google Scholar44. BERNARDWEILBOIRON JMM: Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood 41:489-496, 1973 A good example of the impact this drug has made on the treatment of myeloid leukemias. CrossrefMedlineGoogle Scholar45. JACQUILLATWEILGEMON CMM: Evaluation of 216 four-year survivors of acute leukemia. Cancer 32: 286-293, 1973 An evaluation and review of factors influencing long-term survival. CrossrefMedlineGoogle Scholar46. AURSIMONEHUSTU RJH: Cessation of therapy in childhood acute lymphocytic leukemia. N Engl J Med 291:1230-1234, 1974 Presents the enigma of whether and when therapy should be stopped in a child in long-term remission. CrossrefMedlineGoogle Scholar47. MONFARDINIGEEFRIED STJ: Survival in chronic myelogenous leukemia: influence of treatment and extent of disease at diagnosis. Cancer 31:492-501, 1973 Analysis of a series and a review that demonstrate our failure to have much effect on survival in this disease. CrossrefMedlineGoogle Scholar48. COLLARD-RONGEGOVAERTSHOOGHE EAR: Hairy cell leukemia: functional, immunologic, kinetic and ultrastructural characterization. Blood 46:495-508, 1975 This unusual form of leukemia is being recognized with increasing frequency. CrossrefMedlineGoogle Scholar49. RAISAWITSKYCRONKITE KAE: Clinical staging of chronic lymphocytic leukemia. Blood 46:219-234, 1975 A good review of our current state of knowledge about clinical features of chronic lymphocytic leukemia. CrossrefMedlineGoogle Scholar50. METZGERMOHANAKUMARMILLER RTD: Membranebound immunoglobulins on human leukemic cells. Evidence for humoral immune responses of patients to leukemia-associated antigens. J Clin Invest 56:331-338, 1975 Provides further evidence for the presence of these antigens in human leukemia. CrossrefMedlineGoogle Scholar51. BOGGS D: Transfusion of neutrophils as prevention or treatment of infection in patients with neutropenia. N Engl J Med 290:1055-1062, 1974 Review of the problems and promise of this experimental form of therapy. CrossrefMedlineGoogle Scholar52. HOHNLEHRER DR: NADPH oxidase deficiency in x-linked chronic granulomatous disease. J Clin Invest 55: 707-713, 1975 Reviews and adds to our knowledge of the biochemical defects in this syndrome. CrossrefMedlineGoogle Scholar53. ULTMANNMORAN JE: Clinical course and complications in Hodgkin's disease. Arch Intern Med 131:332-353, 1973 A comprehensive review of the patterns of tissue involvement and complications associated with Hodgkin's disease. CrossrefMedlineGoogle Scholar54. ROSENBERGKAPLAN SH: The management of Stages I, II, and III Hodgkin's disease with combined radiotherapy and chemotherapy. Cancer 35:55-63, 1975 Reports 5-year survival in 90% of 213 patients with stage IA through IIIB Hodgkin's disease. Addition of chemotherapy to radiotherapy appears to prolong disease-free interval but not survival. CrossrefMedlineGoogle Scholar55. GOLDSMITHCARTER MS: Combination chemotherapy of advanced Hodgkin's disease. Cancer 33:1-8, 1974 A review of the various chemotherapeutic programs that have been used in advanced Hodgkin's disease. CrossrefMedlineGoogle Scholar56. KAPLANROSENBERG HS: The management of Hodgkin's disease. Cancer 36:796-803, 1975 Detailed guidelines concerning the increasingly complex (and controversial) approach to various stages and histopathologic classification of Hodgkin's disease. CrossrefMedlineGoogle Scholar57. ROSNERGRUNWALD FH: Hodgkin's disease and acute leukemia: report of eight cases and review of the literature. Am J Med 58:339-353, 1975 Provides further evidence that our current, curative therapy for Hodgkin's disease is also leukemogenic in a small but significant percentage of patients. CrossrefMedlineGoogle Scholar58. HELLMANROSENTHALMOLONEY SDW: The treatment of non-Hodgkin's lymphoma. Cancer 36:804-808, 1975 An excellent brief overview of present concepts in the treatment of non-Hodgkin's lymphoma. Important features that distinguish Hodgkin's disease from non-Hodgkin's lymphoma are discussed. CrossrefMedlineGoogle Scholar59. JOHNSONCHRETIENO'CONOR RPG: Radiotherapeutic implications of prospective staging in non-Hodgkin's lymphoma. Radiology 110:655-657, 1974 One-hundred consecutive untreated patients were evaluated with careful staging, including laparotomy. The authors conclude that radiotherapy techniques used in Hodgkin's disease may be inappropriate in many, if not most, cases of non-Hodgkin's lymphoma. CrossrefMedlineGoogle Scholar60. EDITORIAL: Membrane markers in lymphoproliferative disorders. Lancet 1:670-671, 1975 A good concise statement of recent developments in the classification of lymphoproliferative disorders on the basis of cell surface characteristics. MedlineGoogle Scholar61. LEVIWIERNIK JP: Management of mycosis fungo-ides—current status and future prospects. Medicine (Baltimore) 54:73-88, 1975 An excellent review, with a call for more extensive staging procedures and, in some cases, clinical trials of more aggressive therapy. CrossrefMedlineGoogle Scholar62. LUTGNEREDELSONSCHEIN MRP: Cutaneous T-cell lymphomas: the Sézary syndrome, mycosis fungoides, and related disorders. Ann Intern Med 83:534-552, 1975 An interesting discussion of the immunologic nature of cells from Sézary's syndrome and mycosis fungoides. LinkGoogle Scholar63. WELLSFUDENBERG JH: Paraproteinemias. DM 1-45, February 1974 A well-written review of the biochemistry of immunoglobulins, as well as the clinical features and management of various disorders associated with paraproteinemia. Google Scholar64. ROSNERGRÜNWALD FH: Multiple myeloma terminating in acute leukemia. Report of 12 cases and review of the literature. Am J Med 57:927-939, 1974 A comprehensive review of the increasingly recognized association of acute myeloblastic leukemia and myeloma. CrossrefMedlineGoogle Scholar65. SALMON S: Immunoglobulin synthesis and tumor kinetics of multiple myeloma. Semin Hematol 10:135-147, 1973 An interesting discussion of tumor kinetics and response to therapy, based on the assessment of total body burden of myeloma cells. MedlineGoogle Scholar66. Report of the Medical Research Council's Working Party for Therapeutic Trials in Leukemia. Report of the first myelomatosis trial. Part 1. Analysis of presenting features of prognostic importance. Br J Haematol 24:123-139, 1973 CrossrefMedlineGoogle Scholar This is one of three recent articles on the prognostic factors in untreated myeloma (also, Arch Intern Med 135:46-52, 1975, and Cancer 36:1192-1201, 1975). MedlineGoogle Scholar67. RAISZLUBENMUNDY LRG: Effect of osteoclast activating factor from human leukocytes on bone metabolism. J Clin Invest 56:408-413, 1975 Normal human leukocytes cultured with phytohemagglutinin release, a factor that produces bone resorption which may play a pathologic role in diseases such as multiple myeloma. CrossrefMedlineGoogle Scholar68. SKIPPERSCHABEL HF: Quantitative and cytokinetic studies in experimental tumor models, in Cancer Medicine, edited by HOLLAND JF, FREI E. Philadelphia, Lea & Febiger, 1973, pp. 629-650 This chapter, in an excellent book, provides a good review of the basic information concerning tumor kinetics and its applicability to human cancer. Google Scholar69. WITTLIFF J: Specific receptors of the steroid hormones in breast cancer. Semin Oncol 1:109-118, 1974 Relates responsiveness in endocrine manipulation of breast cancer to the presence or absence of estrogen receptors in general. If these receptors are present, patients have a 50% chance of response; if absent, there is little chance of response. MedlineGoogle Scholar70. FISHERGREGORIOFISHER ERB: The pathology of invasive breast cancer. Cancer 36:1-85, 1975 Contains many clinical correlations between breast cancer and its outcome, the most important of which is the confirmation that metastasis to axillary nodes, particularly more than four, is a poor prognostic sign. CrossrefMedlineGoogle Scholar71. BONADONNABRUSAMOLINOVALAGUSSA GEP: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405-410, 1976 An important study representing a potential major advance in management of early, poor-risk breast cancer. CrossrefMedlineGoogle Scholar72. EDGINGTONASTARITAPLOW TRE: Association of an isomeric species of carcinoembryonic antigen with neoplasia of the gastrointestinal tract. N Engl J Med 293:103-107, 1975 Reviews the subject of carcinoembryonic antigen, and also the development of a more specific carcinoembryonic antigen for detecting gastrointestinal cancers with a much lower false-positive rate than nonspecific carcinoembryonic antigen. CrossrefMedlineGoogle Scholar73. CLARKAINSWORTHBERNARDINO WAE: The developmental biology of primary human malignant melanomas. Semin Oncol 2:83-103, 1975 A review of the important status of the present classification of melanomas, on the basis of which prognostic indicators can be derived from the type of melanoma as judged from its penetration in patients without regional metastases. MedlineGoogle Scholar74. FREIJAFFETATTERSALL ENM: New approaches to cancer chemotherapy with methotrexate. N Engl J Med 292:846-851, 1975 A valuable article that reviews the rationale and mechanisms of action of megadose methotrexate and summarizes the spectacular responses of osteogenic sarcoma to methotrexate when used as an adjuvant form of therapy to surgery. CrossrefMedlineGoogle Scholar75. ROBBOYHERBSTSCULLY SAR: Clear-cell adenocarcinoma of the vagina and cervix in young females: analysis of 37 tumors that persisted or recurred after primary therapy. Cancer 34:606-614, 1974 An important reminder of the association between diethylstilbesterol taken during pregnancy and the subsequent development of clear-cell adenocarcinomas of the lower genital tract in young women. CrossrefMedlineGoogle Scholar76. ROSENOFFYOUNGANDERSON SRT: Peritoneoscopy: a valuable staging tool in ovarian carcinoma. Ann Intern Med 83:37-41, 1975 Describes the inadequacy of most present staging procedures for ovarian carcinoma and indicates one of the reasons adjuvant chemotherapy is likely to be of great benefit in this disease. LinkGoogle Scholar77. BENFIELDJUILLARDPILCH JGY: Current and future concepts of lung cancer. Ann Intern Med 83:93-106, 1975 Reviews virtually all of the aspects of lung cancer that are important in regard to diagnosis, staging, and future potential for early diagnosis and immunotherapy. LinkGoogle Scholar78. REYNOLDSGREENBERGMARTIN RBN: Usefulness of bone marrow serum acid phosphatase in staging carcinoma of the prostate. Cancer 32:181-184, 1973 A good review for those interested in tumor immunology, blocking factor, and the role of host's immunity in malignancy. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: MEDICAL KNOWLEDGE SELF-ASSESSMENT PROGRAM IV AMERICAN COLLEGE OF PHYSICIANS Philadelphia, Pennsylvania*William J. Williams, M.D., F.A.C.P., Chairman; Frank H. Gardner, M.D., F.A.C.P.; John R. Durant, M.D., F.A.C.P.; Dane R. Boggs, M.D.; Peter White, M.D.; Gibbons G. Cornwell, III, M.D., F.A.C.P.; and Patrick Growney, M.D.Reprints are not available.†Computer literature-file of the National Library of Medicine, Bethesda; Maryland, consulted through the Regional Medical Library service Library of the College of Physicians of Philadelphia, with the technical assistance of Ruthanne Henner. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 June 1976Volume 84, Issue 6Page: 758-762KeywordsComputersHematology and oncologyLibraries Issue Published: 1 June 1976 PDF downloadLoading ...